GO
Loading...

Eli Lilly and Co

More

  • Eli Lilly Receives New FDA Approval For Evista Friday, 14 Sep 2007 | 8:25 AM ET

    Drug developer Eli Lilly said Friday the Food and Drug Administration approved its osteoporosis drug Evista for use in reducing the risk of invasive breast cancer.

  • Byetta: What We Know Right Now Monday, 10 Sep 2007 | 3:36 PM ET

    For some time now I've been occasionally blogging about the data on a once-a-week version of Byetta that are expected in the fourth quarter sometime. This is a long-acting release (LAR, for short) version of the current twice-a-day injectable drug for diabetes from Lilly and Amylinspacer. Alkermes makes the technology that extends the drug's release.

  • Amylin's Byetta LAR: Wait Is On For Results Thursday, 6 Sep 2007 | 4:08 PM ET

    An update from the NewsMakers in Biotech conference in NYC on an item of intense interest. Amylin Pharmaceuticals just held a well-attended PowerPoint presentation followed by a very cramped breakout session. And pretty much the only thing investors and analysts wanted to talk about is Byetta LAR (long-acting release).

  • Big Pharma Outlook Wednesday, 5 Sep 2007 | 8:52 PM ET

    Does the thought of raking leaves and covering the patio furniture make you sick? Well, you might be happy to hear that drug maker Eli Lilly is up 10% year to date. But, does your medicine cabinet hold a prescription to profits?

  • Tech, Drug Firms Battle Over Patent Reform Monday, 3 Sep 2007 | 9:14 PM ET

    U.S. lawmakers returning from their summer break are expected to consider patent law changes that have pitted two of America's most invention-dependent industries against each other.

  • Dendreon Provenge, Pfizer's Viagra Ads: Your Emails Wednesday, 29 Aug 2007 | 1:28 PM ET

    I'll be out of the office for an extra-long holiday weekend, so I'm emptying out the blog inbox before I go. Nick Stavriotis sent an email to clarify his previous incomplete statement regarding the FDA's "overrule" of the Dendreon Provenge advisory committee recommendation: "...my words should have said 'refusal to follow an overwhelming...

  • Neurochem And Alzheimer's: Breaking Code Not Easy Monday, 27 Aug 2007 | 2:35 PM ET

    Shares of Neurochem today are trading at a new low after the Canadian biotech announced its developmental drug for Alzheimer's didn't work well enough. It is the latest evidence that cracking the code of this complex disease is extremely challenging. We recently did a story on the drug called Alzhemed, the potential AD-drug market and other companies working on treatments/cures at a dementia conference in Washington, DC.

  • Still Got It Friday, 24 Aug 2007 | 1:16 PM ET

    A sex study published in the New England Journal of Medicine Thursday showed that people in their 70’s and 80’s are more sexually active than previously thought. More than a quarter of seniors up to age 85 reported having sex in the previous year.  What's the trade?

  • Your First Move For Friday August 24th Friday, 24 Aug 2007 | 1:10 PM ET

    Here's our Fast Money Final Trade. Our guys give you tomorrow's best trades, right now!

  • Diabetes: Does Novo Nordisk Signal Big Developments? Monday, 20 Aug 2007 | 12:28 PM ET

    Novo Nordisk, the world's biggest diabetes drug company, is very lightly traded on the New York Stock Exchange, but check out the move in the stock today. Coincidentally, on the day that The New York Times runs a front-page story (with two jump pages) on how controlling diabetes is about lowering blood sugar and cholesterol levels, the Danish drugmaker is out with major data on its glucose fighting drug Liraglutide.

  • Buying into Byetta Wednesday, 15 Aug 2007 | 3:22 PM ET
    Amylin

    Shares of Amylin Pharmaceuticals and Alkermes are rallying today after FBR Biotech Analyst, Jim Reddoch, put out a research note saying the once-a-week diabetes drug they're working on could be a $3 billion-a-year seller. AMLN shares have been on a tear in recent months, rising from about $37 in March to nearly $50 today. That's on investor anticipation of robust test results and continued speculation that AMLN could get taken out.

  • Pharmaceutical company Novo Nordisk, the world's largest producer of insulin, said Friday that second-quarter net profit more than doubled and raised its guidance for the full year. Its shares rose more than 4%.

  • Glaxo's $25 Billion Stock "Prescription" Remedy Wednesday, 25 Jul 2007 | 11:56 AM ET

    GlaxoSmithKline is rallying today after reporting that second quarter sales of its diabetes drug Avandia, fell 31% in the U.S. from the same time a year ago. And from the first quarter of this year to the second quarter, revenue in the U.S. from the blockbuster pill slid $120 million. So, why are investors buying the beaten-down stock?

  • Stocks ended sharply lower on several disappointing earnings reports and concerns about the housing industry. "The housing story has gone from bad to worse. It's pretty clear that the subprime market is not as well contained as a lot of people had been thinking," said David Rosenberg, North American economist at Merrill Lynch.

  • With little or no fanfare Pfizer launched a new ad campaign for its erectile dysfunction drug Viagra on NBC Nightly News last night. Pfizer has gotten into a bit of trouble before for its relatively racy Viagra spots like the "Horny Devil" campaign featuring the guy with two horns growing out of his head. This time it's got a bunch of 40-something guys sitting around a dusty barn singing "Viva Viagra" to the tune of Elvis' "Viva Las Vegas".

  • Lilly Beats Second-Quarter Forecasts, Raises 2007 View Tuesday, 24 Jul 2007 | 8:01 AM ET

    Eli Lilly Tuesday posted better-than-expected second-quarter earnings helped by surging sales of its prescription drugs, including depression treatment Cymbalta, and the company raised its 2007 profit forecast.

  • Court Rules in Favor of Ariad in Eli Lilly Suit Monday, 9 Jul 2007 | 5:26 PM ET

    Ariad Pharmaceuticals said a U.S. federal court ruled in favor of it and co-complainants in a patent infringement case against Eli Lilly, saying that the patent was valid and enforceable.

  • Market pros will be looking closely at the tech sector in the upcoming earnings season, but for investors seeking a quick pop, they need look no further than the energy sector as oil prices remain at record levels.

  • Avandia Fight: Drs. Nissen And Home "Battle" Over Drug Tuesday, 26 Jun 2007 | 11:33 AM ET
    GlaxoSmithKline's Avandia

    The huge auditorium at the McCormick Place Convention Center was packed to the rafters. It was standing room only in the 45-hundred seat theater, although the fire department wouldn't let people stand. The doctors, scientists, and educators at the American Diabetes Association's Annual Meeting came to see the rock stars of their world--Dr. Steven Nissen who wrote the controversial New England Journal of Medicine report questioning the safety of GlaxoSmithKline's Avandia and Dr. Phillip Home who wrote--also in NEJM--the subsequent interim analysis of a GSK-sponsored study that, so far, supports Avandia's safety.

  • Knowin' When to Hold 'Em Tuesday, 12 Jun 2007 | 7:01 PM ET

    If you’re dead set on cradling your drugmaker darlings, there are only a few Cramer thinks are worth owning.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.